Monday, May 19, 2014
At last week's FDA
patient-focused drug development meeting, pulmonary arterial hypertension
patients credited marketed vasodilators with saving their lives, but said
dyspnea and fatigue are still crippling. Clinicians say targeting the
underlying inflammatory and fibrotic elements of the disease could help
ameliorate those two key symptoms.
The message has not been lost
on industry, as a handful of molecules are in early stage clinical development
that could address some of the other elements of PAH.